Cullinan Therapeutics Inc CGEM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
-
Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer
-
Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Trading Information
- Previous Close Price
- $14.10
- Day Range
- $13.44–14.18
- 52-Week Range
- $6.73–23.19
- Bid/Ask
- $13.64 / $16.50
- Shares Outstanding
- 64.35M
- Market Cap
- $877.80M
- Volume/Avg
- 903,554 / 871,867
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 109
Valuation
|
Metric
|
CGEM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.82 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CGEM
|
|---|---|
Quick Ratio | 8.23 |
Current Ratio | 8.42 |
Interest Coverage | — |
Quick Ratio
CGEM
Profitability
|
Metric
|
CGEM
|
|---|---|
Return on Assets (Normalized) | −38.71% |
Return on Equity (Normalized) | −42.12% |
Return on Invested Capital (Normalized) | −46.17% |
Return on Assets
CGEM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^MyhBB | LOCK|y^&R | $126B | |||
| Moderna Inc
MRNA
| LOCK|G^$#qZ | LOCK|ky | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|f%d@&B | LOCK|#xK!@ | $80B | |||
| argenx SE ADR
ARGX
| LOCK|c#s%mB$ | LOCK|?L | $53B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?R$XJM | LOCK|>yW | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$xJm<& | LOCK|!N?Dt | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|j<rd%^$ | LOCK|#h@F | $26B | |||
| Incyte Corp
INCY
| LOCK|KXhY$S& | LOCK|?TM | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|Gy>^GH | LOCK|>PX | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|>VmY?& | LOCK|Tmt | $14B |
United States